Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 72 articles: HTML format

Single Articles

October 2024
1. SARGEN MR, Barnhill RL, Elder DE, Swetter SM, et al
   Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.
   J Clin Oncol. 2024 Oct 4:JCO2401154. doi: 10.1200/JCO.24.01154.
   PubMed     Abstract available
   
   
   September 2024
2. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
   Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
   J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
   PubMed     Abstract available
   
   
   August 2024
3. LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al
   First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
   J Clin Oncol. 2024 Aug 13:JCO2401125. doi: 10.1200/JCO.24.01125.
   PubMed     Abstract available
   
   
   
4. WEBER J, Del Vecchio M, Mandala M, Gogas H, et al
   Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
   J Clin Oncol. 2024 Aug 5:JCO2301448. doi: 10.1200/JCO.23.01448.
   PubMed     Abstract available
   
   
   July 2024
5. HARBOUR JW, Correa ZM, Schefler AC, Mruthyunjaya P, et al
   15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
   J Clin Oncol. 2024 Jul 25:JCO2400447. doi: 10.1200/JCO.24.00447.
   PubMed     Abstract available
   
   
   June 2024
6. HAMID O, Lewis KD, Weise A, McKean M, et al
   Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
   J Clin Oncol. 2024 Jun 20:JCO2302172. doi: 10.1200/JCO.23.02172.
   PubMed     Abstract available
   
   
   March 2024
7. SCHENK KM, Deutsch JS, Chandra S, Davar D, et al
   Nivolumab + Tacrolimus + Prednisone +/- Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
   J Clin Oncol. 2024;42:1011-1020.
   PubMed     Abstract available
   
   
   
8. LUKE JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, et al
   Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
   J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355.
   PubMed     Abstract available
   
   
   February 2024
9. 
   Expression of Concern: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
   J Clin Oncol. 2024 Feb 23:JCO2400161. doi: 10.1200/JCO.24.00161.
   PubMed    
   
   
   
10. VAREY AHR, Li I, El Sharouni MA, Simon J, et al
    Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
    J Clin Oncol. 2024 Feb 5:JCO2301020. doi: 10.1200/JCO.23.01020.
    PubMed     Abstract available
    
    
    
11. 
    Erratum: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
    J Clin Oncol. 2024 Feb 1:JCO2400017. doi: 10.1200/JCO.24.00017.
    PubMed    
    
    
    December 2023
12. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    September 2023
13. 
    Erratum: Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2023 Sep 18:JCO2301773. doi: 10.1200/JCO.23.01773.
    PubMed    
    
    
    August 2023
14. DIAB A, Gogas H, Sandhu S, Long GV, et al
    Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
    J Clin Oncol. 2023 Aug 31:JCO2300172. doi: 10.1200/JCO.23.00172.
    PubMed     Abstract available
    
    
    
15. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    PubMed     Abstract available
    
    
    
16. SETH R, Agarwala SS, Messersmith H, Alluri KC, et al
    Systemic Therapy for Melanoma: ASCO Guideline Update.
    J Clin Oncol. 2023 Aug 14:JCO2301136. doi: 10.1200/JCO.23.01136.
    PubMed     Abstract available
    
    
    
17. 
    Retraction: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    J Clin Oncol. 2023 Aug 11:JCO2301358. doi: 10.1200/JCO.23.01358.
    PubMed    
    
    
    July 2023
18. ASCIERTO PA, Dummer R, Gogas HJ, Arance A, et al
    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
    J Clin Oncol. 2023 Jul 28:JCO2202322. doi: 10.1200/JCO.22.02322.
    PubMed     Abstract available
    
    
    
19. ZHANG X, Ferris L, Faries MB, Luke JJ, et al
    Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
    J Clin Oncol. 2023 Jul 6:JCO2300255. doi: 10.1200/JCO.23.00255.
    PubMed    
    
    
    June 2023
20. ROBERT C, Carlino MS, McNeil C, Ribas A, et al
    Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
    J Clin Oncol. 2023 Jun 22:JCO2201599. doi: 10.1200/JCO.22.01599.
    PubMed     Abstract available
    
    
    
21. OLSON DJ, Odunsi K
    Adoptive Cell Therapy for Nonhematologic Solid Tumors.
    J Clin Oncol. 2023;41:3397-3407.
    PubMed     Abstract available
    
    
    
22. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    PubMed     Abstract available
    
    
    
23. RIELY GJ, Smit EF, Ahn MJ, Felip E, et al
    Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300774. doi: 10.1200/JCO.23.00774.
    PubMed     Abstract available
    
    
    April 2023
24. LONG GV, Menzies AM, Scolyer RA
    Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    J Clin Oncol. 2023 Apr 27:JCO2202575. doi: 10.1200/JCO.22.02575.
    PubMed     Abstract available
    
    
    March 2023
25. DE BRAUD F, Dooms C, Heist RS, Lebbe C, et al
    Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
    J Clin Oncol. 2023 Mar 22:JCO2202018. doi: 10.1200/JCO.22.02018.
    PubMed     Abstract available
    
    
    
26. PHADKE MS, Smalley KSM
    Targeting NRAS Mutations in Advanced Melanoma.
    J Clin Oncol. 2023 Mar 22:JCO2300205. doi: 10.1200/JCO.23.00205.
    PubMed    
    
    
    
27. OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al
    Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705.
    PubMed     Abstract available
    
    
    
28. 
    Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed CellDeath Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2023 Mar 20:JCO2300439. doi: 10.1200/JCO.23.00439.
    PubMed    
    
    
    
29. 
    Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385.
    PubMed    
    
    
    February 2023
30. DEVLIN O, Oladipo O
    Sequencing of Targeted Treatment and Immunotherapy in Advanced BRAF-Mutant Melanoma.
    J Clin Oncol. 2023 Feb 15:JCO2202250. doi: 10.1200/JCO.22.02250.
    PubMed    
    
    
    
31. ASCIERTO PA, Lipson EJ, Dummer R, Larkin J, et al
    Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
    J Clin Oncol. 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072.
    PubMed     Abstract available
    
    
    
32. TOPALIAN SL, Sznol M, McDermott DF, Kluger HM, et al
    Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
    J Clin Oncol. 2023;41:943-954.
    PubMed     Abstract available
    
    
    
33. SCHWARTZ GK
    Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety.
    J Clin Oncol. 2023;41:941-942.
    PubMed    
    
    
    January 2023
34. KIRKWOOD JM, Strawderman MH, Ernstoff MS, Smith TJ, et al
    Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
    J Clin Oncol. 2023;41:425-435.
    PubMed     Abstract available
    
    
    
35. SCHWARTZ GK
    Flashback Foreword: Adjuvant Interferon alpha-2b for High-Risk Melanoma.
    J Clin Oncol. 2023;41:423-424.
    PubMed    
    
    
    December 2022
36. MANGLA A
    Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.
    J Clin Oncol. 2022 Dec 1:JCO2201903. doi: 10.1200/JCO.22.01903.
    PubMed    
    
    
    
37. HINDIE E
    Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma.
    J Clin Oncol. 2022 Dec 1:JCO2201963. doi: 10.1200/JCO.22.01963.
    PubMed    
    
    
    November 2022
38. BOUFFET E, Geoerger B, Moertel C, Whitlock JA, et al
    Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
    J Clin Oncol. 2022 Nov 14:JCO2201000. doi: 10.1200/JCO.22.01000.
    PubMed     Abstract available
    
    
    September 2022
39. ATKINS MB, Lee SJ, Chmielowski B, Tarhini AA, et al
    Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134.
    J Clin Oncol. 2022 Sep 27:101200JCO2201763. doi: 10.1200/JCO.22.01763.
    PubMed     Abstract available
    
    
    
40. WEBER JS, Schadendorf D, Del Vecchio M, Larkin J, et al
    Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
    J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533.
    PubMed     Abstract available
    
    
    
41. AUGUSTIN RC, Luke JJ
    Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
    J Clin Oncol. 2022 Sep 26:JCO2201770. doi: 10.1200/JCO.22.01770.
    PubMed    
    
    
    
42. CHANDRA S, Choi JS, Sosman JA
    Melanoma: Does Sequencing Really Matter?
    J Clin Oncol. 2022 Sep 20:JCO2201354. doi: 10.1200/JCO.22.01354.
    PubMed    
    
    
    
43. ASCIERTO PA, Mandala M, Ferrucci PF, Guidoboni M, et al
    Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
    J Clin Oncol. 2022 Sep 1:JCO2102961. doi: 10.1200/JCO.21.02961.
    PubMed     Abstract available
    
    
    August 2022
44. CHESNEY JA, Ribas A, Long GV, Kirkwood JM, et al
    Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
    J Clin Oncol. 2022 Aug 23:JCO2200343. doi: 10.1200/JCO.22.00343.
    PubMed     Abstract available
    
    
    July 2022
45. ARANCE A, de la Cruz-Merino L, Petrella TM, Jamal R, et al
    Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2022 Jul 22:JCO2200221. doi: 10.1200/JCO.22.00221.
    PubMed     Abstract available
    
    
    
46. DUMMER R, Flaherty KT, Robert C, Arance A, et al
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2022 Jul 21:JCO2102659. doi: 10.1200/JCO.21.02659.
    PubMed     Abstract available
    
    
    
47. SULLIVAN RJ
    What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?
    J Clin Oncol. 2022 Jul 21:JCO2201066. doi: 10.1200/JCO.22.01066.
    PubMed    
    
    
    
48. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
    Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    J Clin Oncol. 2022 Jul 18:JCO2102488. doi: 10.1200/JCO.21.02488.
    PubMed     Abstract available
    
    
    June 2022
49. GARBE C, Keim U, Amaral T, Berking C, et al
    Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
    J Clin Oncol. 2022 Jun 16:JCO2200202. doi: 10.1200/JCO.22.00202.
    PubMed     Abstract available
    
    
    
50. SETH R, Messersmith H, Funchain P
    Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Jun 3:JCO2200944. doi: 10.1200/JCO.22.00944.
    PubMed     Abstract available
    
    
    March 2022
51. OLIVIER T, Prasad V
    Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102904. doi: 10.1200/JCO.21.02904.
    PubMed    
    
    
    
52. CARVAJAL RD, Nathan P, Sacco JJ, Orloff M, et al
    Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    J Clin Oncol. 2022 Mar 7:JCO2101805. doi: 10.1200/JCO.21.01805.
    PubMed     Abstract available
    
    
    February 2022
53. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available
    
    
    January 2022
54. CALLAHAN MK, Chapman PB
    PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2102801. doi: 10.1200/JCO.21.02801.
    PubMed    
    
    
    
55. DUMMER R, Long GV, Robert C, Tawbi HA, et al
    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2101601. doi: 10.1200/JCO.21.01601.
    PubMed     Abstract available
    
    
    December 2021
56. POSTOW MA, Goldman DA, Shoushtari AN, Betof Warner A, et al
    Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570.
    PubMed     Abstract available
    
    
    November 2021
57. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229.
    PubMed     Abstract available
    
    
    August 2021
58. ANDTBACKA RHI, Curti B, Daniels GA, Hallmeyer S, et al
    Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    J Clin Oncol. 2021 Aug 31:JCO2003246. doi: 10.1200/JCO.20.03246.
    PubMed     Abstract available
    
    
    July 2021
59. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed     Abstract available
    
    
    June 2021
60. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.
    PubMed    
    
    
    
61. CHAPMAN PB
    Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
    J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.
    PubMed    
    
    
    May 2021
62. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available
    
    
    
63. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available
    
    
    February 2021
64. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available
    
    
    January 2021
65. SHOUSHTARI AN
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.
    PubMed    
    
    
    
66. HINDIE E
    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.
    PubMed    
    
    
    
67. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available
    
    
    
68. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available
    
    
    
69. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.
    PubMed    
    
    
    October 2020
70. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available
    
    
    September 2020
71. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available
    
    
    April 2020
72. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.